Cerus Corporation to Release First Quarter 2020 Financial Results on May 5, 2020
Cerus Corporation (Nasdaq:CERS) announced today that its first
quarter 2020 financial results will be released on Tuesday, May 5,
2020, after the close of the stock market. The Company will host a
conference call and webcast at 4:30 P.M. ET that afternoon, during
which management will discuss the Company’s financial results and
provide a general business overview and outlook.
To access the live webcast, please visit the Investor Relations
page of the Cerus website at http://www.cerus.com/ir.
Alternatively, you may access the live conference call by dialing
(866) 235-9006 (U.S.) or (631) 291-4549 (international).
A replay will be available on Cerus’ website, or by dialing
(855) 859-2056 (U.S.) or (404) 537-3406 (international) and
entering conference ID number 8484403. The replay will be available
approximately three hours after the call through May 19, 2020.
Cerus Corporation is dedicated solely to safeguarding the
world’s blood supply and aims to become the preeminent global blood
products company. Based in Concord, California, our employees are
dedicated to deploying and supplying vital technologies and
pathogen-protected blood components for blood centers, hospitals
and ultimately patients who rely on safe blood. With the INTERCEPT
Blood System, we are focused on protecting patients by delivering
the full complement of reliable products and expertise for
transfusion medicine. Cerus develops and markets the INTERCEPT
Blood System and remains the only company in the blood transfusion
space to earn both CE Mark and FDA approval for pathogen reduction
of both platelet and plasma components. Cerus currently markets and
sells the INTERCEPT Blood System in the United States, Europe, the
Commonwealth of Independent States, the Middle East and selected
countries in other regions around the world. The INTERCEPT Red
Blood Cell system is in clinical development. For more information
about Cerus, visit www.cerus.com and follow us on LinkedIn.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus
version on businesswire.com: https://www.businesswire.com/news/home/20200424005069/en/
Tim Lee – Investor Relations Director Cerus Corporation
Historical Stock Chart
From Sep 2020 to Oct 2020
Historical Stock Chart
From Oct 2019 to Oct 2020